QRxPharma

QRxPharma inks strategic collaboration with Paladin Labs

Wednesday, October 10, 2012 11:31 AM

QRxPharma, a commercial-stage specialty pharmaceutical company based in Bedminster, N.J., signed a licensing agreement with Paladin Labs, specialty pharmaceutical company based in Montreal, for the Canadian commercialization rights to Moxduo, a patented, immediate-release formulation of morphine and oxycodone. 

More... »


QRxPharma concludes phase I studies for MoxDuo CR

Wednesday, April 11, 2012 03:28 PM

Australia-based QRxPharma has completed two phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing a 3:2 ratio of morphine and oxycodone.

More... »


Actavis partners with QRxPharma to launch novel pain medication in U.S.

Thursday, December 22, 2011 09:46 AM
Actavis has entered into a binding letter of intent (LOI) with QRxPharma to commercialize MoxDuo IR in the United States.

More... »

QRxPharma files NDA for MoxDuoR IR

Wednesday, July 20, 2011 11:16 AM

QRxPharma reported the initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the FDA.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs